Cargando…
Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
In clinical samples, the expression of androgen receptor (AR) and of AR splice variant 7 (AR-V7) is higher in castration-resistant prostate cancer (CRPC) compared with that in hormone-sensitive prostate cancer (PCa). However, there are only a few reports on the ratio of the expression levels of AR-V...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527558/ https://www.ncbi.nlm.nih.gov/pubmed/34691258 http://dx.doi.org/10.3892/ol.2021.13092 |
_version_ | 1784586091867668480 |
---|---|
author | Sekine, Yoshitaka Nakayama, Hiroshi Miyazawa, Yoshiyuki Arai, Seiji Koike, Hidekazu Matsui, Hiroshi Shibata, Yasuhiro Ito, Kazuto Suzuki, Kazuhiro |
author_facet | Sekine, Yoshitaka Nakayama, Hiroshi Miyazawa, Yoshiyuki Arai, Seiji Koike, Hidekazu Matsui, Hiroshi Shibata, Yasuhiro Ito, Kazuto Suzuki, Kazuhiro |
author_sort | Sekine, Yoshitaka |
collection | PubMed |
description | In clinical samples, the expression of androgen receptor (AR) and of AR splice variant 7 (AR-V7) is higher in castration-resistant prostate cancer (CRPC) compared with that in hormone-sensitive prostate cancer (PCa). However, there are only a few reports on the ratio of the expression levels of AR-V7 to AR (AR-V7/AR) in prostate tissue. The present study evaluated AR-V7/AR expression in various types of human prostate tissues and CRPC cells. Pretreatment prostate tissue samples from patients with benign prostatic hyperplasia (BPH; n=18), Gleason score 7 (n=17), and Gleason score 8–10 (n=26) were collected at the time of prostate biopsy, and tissue samples from CRPC patients (n=10) were collected at the time of transurethral resection of the prostate. Furthermore, androgen-independent LNCaP cells were established. The mRNA expression levels of AR and AR-V7, cell proliferation and prostate-specific antigen (PSA) production were evaluated by reverse transcription quantitative PCR, MTS assay and chemiluminescent enzyme immunoassay, respectively. There was a significant difference in AR-V7/AR expression ratios between the CRPC group and the BPH and pre-treatment PCa groups (CRPC, 7%; BPH and pre-treatment PCa, 1%). Subsequently, we compared the AR and AR-V7 expression levels in CRPC samples with those in the pretreatment prostate tissues from the same patients. The results demonstrated that the AR-V7/AR ratio increased from 3 to 9% after CRPC onset. Furthermore, in vitro experiment demonstrated that AR-V7 expression in LNCaP cells was increased after transforming into CRPC cells. The AR-V7/AR ratio also increased from 0.05 to 0.3%. In addition, small interfering (si)-RNA-mediated knockdown of AR inhibited the proliferation of and PSA production from androgen-independent LNCaP cells; however, AR-V7 knockdown had no effect. Conversely, siRNA-mediated knockdown of both AR and AR-V7 inhibited the proliferation of VCAP cells. In summary, the findings from the present study demonstrated that AR-V7 expression and AR-V7/AR ratio were increased after the onset of CRPC, which had a limited role in CRPC cell proliferation. Further investigation is required to clarify the roles of AR other splice variants and AR-V7 in CRPC. |
format | Online Article Text |
id | pubmed-8527558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-85275582021-10-22 Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer Sekine, Yoshitaka Nakayama, Hiroshi Miyazawa, Yoshiyuki Arai, Seiji Koike, Hidekazu Matsui, Hiroshi Shibata, Yasuhiro Ito, Kazuto Suzuki, Kazuhiro Oncol Lett Articles In clinical samples, the expression of androgen receptor (AR) and of AR splice variant 7 (AR-V7) is higher in castration-resistant prostate cancer (CRPC) compared with that in hormone-sensitive prostate cancer (PCa). However, there are only a few reports on the ratio of the expression levels of AR-V7 to AR (AR-V7/AR) in prostate tissue. The present study evaluated AR-V7/AR expression in various types of human prostate tissues and CRPC cells. Pretreatment prostate tissue samples from patients with benign prostatic hyperplasia (BPH; n=18), Gleason score 7 (n=17), and Gleason score 8–10 (n=26) were collected at the time of prostate biopsy, and tissue samples from CRPC patients (n=10) were collected at the time of transurethral resection of the prostate. Furthermore, androgen-independent LNCaP cells were established. The mRNA expression levels of AR and AR-V7, cell proliferation and prostate-specific antigen (PSA) production were evaluated by reverse transcription quantitative PCR, MTS assay and chemiluminescent enzyme immunoassay, respectively. There was a significant difference in AR-V7/AR expression ratios between the CRPC group and the BPH and pre-treatment PCa groups (CRPC, 7%; BPH and pre-treatment PCa, 1%). Subsequently, we compared the AR and AR-V7 expression levels in CRPC samples with those in the pretreatment prostate tissues from the same patients. The results demonstrated that the AR-V7/AR ratio increased from 3 to 9% after CRPC onset. Furthermore, in vitro experiment demonstrated that AR-V7 expression in LNCaP cells was increased after transforming into CRPC cells. The AR-V7/AR ratio also increased from 0.05 to 0.3%. In addition, small interfering (si)-RNA-mediated knockdown of AR inhibited the proliferation of and PSA production from androgen-independent LNCaP cells; however, AR-V7 knockdown had no effect. Conversely, siRNA-mediated knockdown of both AR and AR-V7 inhibited the proliferation of VCAP cells. In summary, the findings from the present study demonstrated that AR-V7 expression and AR-V7/AR ratio were increased after the onset of CRPC, which had a limited role in CRPC cell proliferation. Further investigation is required to clarify the roles of AR other splice variants and AR-V7 in CRPC. D.A. Spandidos 2021-12 2021-10-13 /pmc/articles/PMC8527558/ /pubmed/34691258 http://dx.doi.org/10.3892/ol.2021.13092 Text en Copyright: © Sekine et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Sekine, Yoshitaka Nakayama, Hiroshi Miyazawa, Yoshiyuki Arai, Seiji Koike, Hidekazu Matsui, Hiroshi Shibata, Yasuhiro Ito, Kazuto Suzuki, Kazuhiro Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
title | Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
title_full | Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
title_fullStr | Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
title_full_unstemmed | Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
title_short | Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
title_sort | ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527558/ https://www.ncbi.nlm.nih.gov/pubmed/34691258 http://dx.doi.org/10.3892/ol.2021.13092 |
work_keys_str_mv | AT sekineyoshitaka ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT nakayamahiroshi ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT miyazawayoshiyuki ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT araiseiji ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT koikehidekazu ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT matsuihiroshi ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT shibatayasuhiro ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT itokazuto ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer AT suzukikazuhiro ratiooftheexpressionlevelsofandrogenreceptorsplicevariant7toandrogenreceptorincastrationrefractoryprostatecancer |